Despite improvements in the treatment of primary uveal melanoma, patients with metastatic disease continue to exhibit poor survival rates . Use of immune checkpoint inhibitors, such as anti-CTLA-4 and anti–PD-1 therapies, were associated with improved survival outcomes . Development of extrahepatic-only metastases, better baseline performance status, and female sex contributed to a more than 2-fold… Continue reading Determinants of overall survival in patients with metastatic uveal melanoma
Tag: Immunotherapy
Determinants of overall survival in patients with metastatic uveal melanoma
Despite improvements in the treatment of primary uveal melanoma, patients with metastatic disease continue to exhibit poor survival rates . Use of immune checkpoint inhibitors, such as anti-CTLA-4 and anti–PD-1 therapies, were associated with improved survival outcomes . Development of extrahepatic-only metastases, better baseline performance status, and female sex contributed to a more than 2-fold… Continue reading Determinants of overall survival in patients with metastatic uveal melanoma
Top advances of the year: Genitourinary cancer
There is now greater clarity on the role of the use of immunotherapies in renal cell carcinoma . Antibody drug conjugates have continued to show activity in urothelial cancer with promising clinical outcomes . Data are also discussed regarding intensification for front-line therapy of metastatic castrate sensitive prostate cancer .
Top advances of the year: Genitourinary cancer
There is now greater clarity on the role of the use of immunotherapies in renal cell carcinoma . Antibody drug conjugates have continued to show activity in urothelial cancer with promising clinical outcomes . Data are also discussed regarding intensification for front-line therapy of metastatic castrate sensitive prostate cancer .
Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer
Patients with DM had a significantly shorter median progression-free survival (PFS) and overall survival . The time on pembrolizumab treatment was shorter in diabetic patients, with only 19.6% remaining on treatment at 12 months compared to 31.7% of the nondiabetic patients . More work is needed to verify our findings and explore similar effects in… Continue reading Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer
Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer
Patients with DM had a significantly shorter median progression-free survival (PFS) and overall survival . The time on pembrolizumab treatment was shorter in diabetic patients, with only 19.6% remaining on treatment at 12 months compared to 31.7% of the nondiabetic patients . More work is needed to verify our findings and explore similar effects in… Continue reading Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer